These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35959522)

  • 1. A prospective multicenter study on cutaneous reactions reported after Sinopharm COVID-19 vaccination.
    Shawky A; Elrewiny EM; Gharib K; Sallam M; Mansour M; Rageh MA
    Int J Dermatol; 2023 Feb; 62(2):221-224. PubMed ID: 35959522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases.
    Català A; Muñoz-Santos C; Galván-Casas C; Roncero Riesco M; Revilla Nebreda D; Solá-Truyols A; Giavedoni P; Llamas-Velasco M; González-Cruz C; Cubiró X; Ruíz-Villaverde R; Gómez-Armayones S; Gil Mateo MP; Pesqué D; Marcantonio O; Fernández-Nieto D; Romaní J; Iglesias Pena N; Carnero Gonzalez L; Tercedor-Sanchez J; Carretero G; Masat-Ticó T; Rodríguez-Jiménez P; Gimenez-Arnau AM; Utrera-Busquets M; Vargas Laguna E; Angulo Menéndez AG; San Juan Lasser E; Iglesias-Sancho M; Alonso Naranjo L; Hiltun I; Cutillas Marco E; Polimon Olabarrieta I; Marinero Escobedo S; García-Navarro X; Calderón Gutiérrez MJ; Baeza-Hernández G; Bou Camps L; Toledo-Pastrana T; Guilabert A
    Br J Dermatol; 2022 Jan; 186(1):142-152. PubMed ID: 34254291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders.
    Seirafianpour F; Pourriyahi H; Gholizadeh Mesgarha M; Pour Mohammad A; Shaka Z; Goodarzi A
    Dermatol Ther; 2022 Jun; 35(6):e15461. PubMed ID: 35316551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological characteristics of cutaneous complications following COVID-19 vaccination: A case series.
    Diab R; Rakhshan A; Salarinejad S; Pourani MR; Ansar P; Abdollahimajd F
    J Cosmet Dermatol; 2024 Mar; 23(3):725-730. PubMed ID: 37899662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complications and Efficacy of Sinopharm Vaccine among Liver and Kidney Transplantation.
    Aliakbarian M; Khodashahi R; Sabbagh MG; Rezayat KA; Khodashahi M; Khaleghi E; Moghaddam MD; Razmkhah B; Nazar MN; Sheikhi N
    Curr Drug Saf; 2023; 18(1):15-22. PubMed ID: 35249504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Reasons for allergology consultations prior to COVID-19 vaccination and their outcomes : Two-year experience of an allergy center in North Rhine-Westphalia].
    Leonidou Floruß E; Demidova A; Hofmann SC; Balakirski G
    Dermatologie (Heidelb); 2023 Jul; 74(7):511-519. PubMed ID: 37140637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID.
    Weaver KN; Zhang X; Dai X; Watkins R; Adler J; Dubinsky MC; Kastl A; Bousvaros A; Strople JA; Cross RK; Higgins PDR; Ungaro RC; Bewtra M; Bellaguarda E; Farraye FA; Boccieri ME; Firestine A; Kappelman MD; Long MD
    Inflamm Bowel Dis; 2022 Oct; 28(10):1497-1505. PubMed ID: 34871388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse cutaneous reactions reported post COVID-19 vaccination in Al Buraimi governorate, Sultanate of Oman.
    Al Salmi A; Al Khamisani M; Al Shibli A; Al Maqbali S
    Dermatol Ther; 2022 Nov; 35(11):e15820. PubMed ID: 36097882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases.
    McMahon DE; Amerson E; Rosenbach M; Lipoff JB; Moustafa D; Tyagi A; Desai SR; French LE; Lim HW; Thiers BH; Hruza GJ; Blumenthal KG; Fox LP; Freeman EE
    J Am Acad Dermatol; 2021 Jul; 85(1):46-55. PubMed ID: 33838206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous adverse reactions of COVID-19 vaccines: A systematic review.
    Qaderi K; Golezar MH; Mardani A; Mallah MA; Moradi B; Kavoussi H; Shamsabadi A; Golezar S
    Dermatol Ther; 2022 May; 35(5):e15391. PubMed ID: 35194894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous manifestations of COVID-19 and COVID-19 vaccination.
    Nakashima C; Kato M; Otsuka A
    J Dermatol; 2023 Mar; 50(3):280-289. PubMed ID: 36636825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous adverse reactions after COVID-19 vaccines in a cohort of 2740 Italian subjects: An observational study.
    Grieco T; Maddalena P; Sernicola A; Muharremi R; Basili S; Alvaro D; Cangemi R; Rossi A; Pellacani G
    Dermatol Ther; 2021 Nov; 34(6):e15153. PubMed ID: 34622531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Self-reported High-Risk Allergy History With Allergy Symptoms After COVID-19 Vaccination.
    Li L; Robinson LB; Patel R; Landman AB; Fu X; Shenoy ES; Hashimoto DM; Banerji A; Wickner PG; Samarakoon U; Mancini CM; Zhang Y; Blumenthal KG
    JAMA Netw Open; 2021 Oct; 4(10):e2131034. PubMed ID: 34698847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Herpes zoster following vaccination with ChAdOx1 nCoV-19 Coronavirus vaccine (recombinant).
    Job AM; Sudhamani B; Mohan M; Mohanasundaram SN
    Indian J Public Health; 2022; 66(1):83-85. PubMed ID: 35381724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global incidence pattern and factors associated with common cutaneous reactions related to COVID-19 vaccination of 2.55 million participants in real-world settings: A systematic review and meta-analysis.
    Guo Y; Cao XS; Yang HT; Zhou MG; Yu B
    J Glob Health; 2023 Feb; 13():06008. PubMed ID: 36757823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
    Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine (Moderna) in a Cohort of Hospital Employees.
    Jacobson MA; Zakaria A; Maung Z; Hart C; McCalmont TH; Fassett M; Amerson E
    Clin Infect Dis; 2022 Mar; 74(4):591-596. PubMed ID: 34086881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.
    Wang J; Hou Z; Liu J; Gu Y; Wu Y; Chen Z; Ji J; Diao S; Qiu Y; Zou S; Zhang A; Zhang N; Wang F; Li X; Wang Y; Liu X; Lv C; Chen S; Liu D; Ji X; Liu C; Ren T; Sun J; Zhao Z; Wu F; Li F; Wang R; Yan Y; Zhang S; Ge G; Shao J; Yang S; Liu C; Huang Y; Xu D; Li X; Ai J; He Q; Zheng MH; Zhang L; Xie Q; Rockey DC; Fallowfield JA; Zhang W; Qi X
    J Hepatol; 2021 Aug; 75(2):439-441. PubMed ID: 33905793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.